Pharming Group NV (PHAR) financial statements
Pharming Group NV reported revenue of $376M in fiscal 2025, up 12.1% a year over 6 years.
Net income was $3M and the operating margin 6.9%, against 36.0% in 2019.
Free cash flow was $54M.
The diluted share count rose 11% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Pharming Group NV's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $189M | $212M | $199M | $206M | $245M | $297M | $376M |
| Cost of revenue | $24M | $24M | $21M | $18M | $25M | $35M | $46M |
| Gross profit | $165M | $189M | $178M | $188M | $220M | $262M | $331M |
| Research and development | $32M | $39M | $70M | $53M | $69M | $83M | $100M |
| Selling, general and admin | $21M | $24M | $37M | $46M | $56M | $71M | $80M |
| Operating income | $68M | $76M | $14M | $18M | -$5M | -$9M | $26M |
| Interest expense | $0 | $74,000 | $94,000 | $105,000 | $134,000 | $56,000 | $196,000 |
| Pre-tax income | $52M | $44M | $23M | $15M | -$12M | -$8M | $13M |
| Income tax | $12M | $6M | $7M | $1M | -$1M | $3M | $10M |
| Net income | $41M | $38M | $16M | $14M | -$11M | -$12M | $3M |
| EPS (diluted) | $0.06 | $0.06 | $0.02 | $0.02 | -$0.02 | -$0.02 | $0.00 |
| Diluted shares | 674M | 683M | 701M | 707M | 725M | 785M | 747M |
| Gross margin | 87.4% | 88.9% | 89.4% | 91.5% | 89.7% | 88.1% | 87.9% |
| Operating margin | 36.0% | 35.9% | 6.8% | 8.9% | -2.2% | -2.9% | 6.9% |
| Net margin | 21.4% | 17.8% | 8.0% | 6.7% | -4.3% | -4.0% | 0.8% |
Balance sheet
Fiscal years, from Pharming Group NV's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $74M | $205M | $192M | $207M | $62M | $55M | $145M |
| Receivables | $29M | $36M | $30M | $28M | $46M | $55M | $55M |
| Inventory | $16M | $21M | $27M | $42M | $57M | $56M | $65M |
| Total current assets | $119M | $263M | $249M | $278M | $316M | $278M | $299M |
| Property, plant and equipment | $10M | $12M | $13M | $10M | $10M | $8M | $7M |
| Total assets | $256M | $418M | $397M | $426M | $463M | $400M | $500M |
| Total current liabilities | $114M | $77M | $47M | $60M | $78M | $74M | $116M |
| Total liabilities | $139M | $235M | $204M | $221M | $244M | $179M | $223M |
| Shareholders' equity | $117M | $183M | $193M | $205M | $219M | $221M | $277M |
| Net debt | -$74M | -$205M | -$192M | -$207M | -$62M | -$55M | -$145M |
Cash flow
Fiscal years, from Pharming Group NV's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $74M | $84M | $38M | $22M | -$17M | -$2M | $55M |
| Capital spending | $3M | $5M | $11M | $1M | $1M | $790,000 | $749,000 |
| Free cash flow | $72M | $79M | $27M | $21M | -$19M | -$3M | $54M |
| Stock-based compensation | $4M | $7M | $9M | $6M | $9M | $11M | $14M |
| Net borrowing | -$35M | -$57M | $0 | $0 | $0 | $105M | $0 |
| Free cash flow margin | 37.8% | 37.2% | 13.6% | 10.3% | -7.6% | -0.9% | 14.3% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PHAR.
Open PHAR in InvestinglyQuestions
What was Pharming Group NV's revenue in 2025?
$376M in fiscal 2025, from its 10-K filing.
How much free cash flow does Pharming Group NV generate?
$54M in fiscal 2025 (operating cash flow minus capital spending).
From Pharming Group NV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.